

# Early and Late Phase Airway Hyperresponsiveness After Aerosol Challenge of Antigen




Figure 1

# Induction of Asthmatic Attack in Normal BALB/c Mice and Effect of Prophylactic C5 Inhibition

<u>Group &amp; Schedule:</u>	<u>day 1, 14</u>	<u>day 25, 29, 32</u>	<u>day 28, 29, 30</u>	<u>day 33</u>
P. Control	Ova + Alum	135.8, 40mg/kg	1% OVA aerosol	5% OVA aerosol
Anti-C5	Ova + Alum	BB5.1, 40mg/kg	1% OVA aerosol	5% OVA aerosol
Steroid	Ova + Alum	Dex	1% OVA aerosol	5% OVA aerosol
N. Control	PBS + Alum	PBS	PBS	PBS

Figure 2a

# The prophylactic treatment schedule




Figure 2b

# Induction of Asthmatic Attack in Normal BALB/c Mice and Effect of Prophylactic C5 Inhibition





Figure 3

# Effect of Therapeutic C5 Inhibition (Aerosol or IV) During Asthmatic Attack


<u>Group &amp;</u>		<u>Schedule: day 1, 14</u>			<u>Aerosol on day 28-30 &amp; day 32</u>			<u>day 35</u>			<u>day 35</u>		
P.Control	Ova + Alum				1% ova on day 29-30, 5% on 32			5% OVA			IV or aerosol 135.8		
Anti-C5	Ova + Alum				1% ova on day 29-30, 5% on 32			5% OVA			IV or aerosol BB5.1		
Steroid	Ova + Alum				1% ova on day 29-30, 5% on 32			5% OVA			IV or aerosol Dex		
N.Control	PBS + Alum				PBS on day 29-30, PBS on 32			PBS			IV or aerosol PBS		

Figure 4a

# Induction of Asthmatic Attack in Balb/c Mice



Increased Airway Resistance Seen In Group of 32 Animals



- Animals were randomized into 6 treatment groups prior next challenge

Figure 4b

# Effect of Aerosol anti-C5 mAb Treatment During Asthmatic Attack




Figure 5a

# Effect of Aerosol anti-C5 mAb Treatment During Asthmatic Attack (Continuous Measurement)




Figure 5b



# Effect of IV anti-C5 mAb Treatment During Asthmatic Attack




Figure 6a

# Effect of IV anti-C5 mAb Treatment During Asthmatic Attack (Continuous Measurement)




Figure 6b

# Serum C5 Activity 6 hr. After Treatment





Figure 7

Effect of Steroid and anti-C5 Treatment on BAL total WBC Count  
(5hr after OVA challenge and mAb treatment)



## Eosinophils are the predominant inflammatory cells in BAL



Fig. 9A: Non-immunized




Fig. 9B: Control mAb




Fig. 9C: Steroid




Fig. 9D: Anti-C5

# BAL WBC Differential Analysis






Fig. 10

# Effect of Steroid and anti-C5 Treatment on BAL Histamine Level (5hr after OVA challenge and mAb treatment)




**New Data: Effect of Steroid and anti-C5 Treatment on BAL MMP-9 Level  
(5hr after OVA challenge and mAb treatment)**





# Steroid and Anti-C5 mAb Treatment Block the Production of TGF-beta During Asthmatic Attack



# Test the Direct & Immediate Bronchial Dilation Effect of C5 Inhibitor Or In Combination with Salbutamol During Wheezing (Provocation with Allergen)

Cannulation & Aerosol C5 inhibitor or  $\beta_2$  agonist & Testing RL simultaneously

Aerosol 5% OVA

IP OVA & Alum

Aerosol 1% OVA

on day 32 & 35

↓ ↓ ↓ ↓ ↓ ↓

Day 1 14 28 29 30




Fig. 14

Fig. 15

# Test the Direct & Immediate Bronchial Dilation Effect of C5 Inhibitor Or In Combination with Salbutamol During Wheezing

